Sepalna (senaparib)

Where it stands

Sepalna (senaparib) received a positive CHMP opinion on 17 September 2026. The records list its status as "Opinion" and show no approval date, so it has no EU marketing authorisation yet. The company is blank in the records, so the applicant cannot be named here.

The recorded indication is maintenance treatment of advanced epithelial high-grade ovarian, fallopian tube or primary peritoneal cancer. The therapeutic areas are listed as ovarian epithelial carcinoma, fallopian tube neoplasms and peritoneal neoplasms. The records do not give the line of therapy, any biomarker or prior-treatment restrictions, or the final wording of the product information. Any such limits would only be visible in the CHMP documents.

A CHMP positive opinion is a scientific recommendation, not an authorisation. Legal authorisation for the EU comes from a European Commission (EC) decision, which normally follows the opinion.

Regulatory pathway and designations

No designations are recorded for this product. The records do not say whether it has orphan status, PRIME support, accelerated assessment or a conditional marketing authorisation. They also do not say whether the pathway was standard. None of these should be assumed from the absence of data.

The records give one forward-looking milestone, an expected EC decision on 23 November 2026. This is marked as an estimate and not an official date. It is calculated as the CHMP opinion date plus 67 days, which the record describes as the standard Commission decision period.

In general, the Commission prepares a draft decision after the opinion, consults the Member States through the Standing Committee, and then adopts the decision. The actual date can differ from the estimate. Once adopted, the decision applies across all EU Member States, with EEA countries following.

Safety and pharmacovigilance

The records contain no safety data, risk management plan details, warnings, contraindications or post-authorisation commitments for Sepalna, so no safety assessment can be made from them.

What to watch

The main event is the EC decision, currently estimated for 23 November 2026. It should be treated as indicative until the Commission publishes the decision. Readers should check that the authorised indication matches the one recorded.

Once the CHMP publishes its assessment documents, the product information and the EPAR should answer the points the records leave open. These include the exact indication wording, any restrictions, the safety profile, risk-minimisation measures and any conditions attached to the authorisation. The applicant's identity and any national launch or reimbursement steps are also not covered by the records.